Introduction of Vaccinomics to Develop Personalized Vaccines in Light of Changes in the Usage of Hantaan Virus Vaccine (Hantavax®) in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The Ministry of Food and Drug Safety of Korea made an official announcement in March 2018 that the total number of inoculations of Hantaan virus vaccine (Hantavax®) would change from 3 to 4. Some aspects of this decision remain controversial. Based on the characteristics of Hantaan virus (HTNV) and its role in the pathogenesis of hemorrhagic fever with renal syndrome, it might be difficult to develop an effective and safe HTNV vaccine through the isolate-inactivate-inject paradigm. With the development of high-throughput ‘omics’ technologies in the 21st century, vaccinomics has been introduced. While the goal of vaccinomics is to develop equations to describe and predict the immune response, it could also serve as a tool for developing new vaccine candidates and individualized approaches to vaccinology. Thus, the possibility of applying the innovative field of vaccinomics to develop a more effective and safer HTNV vaccine should be considered.
Abstract
The Ministry of Food and Drug Safety of Korea made an official announcement in March 2018 that the total number of inoculations of Hantaan virus vaccine (Hantavax®) would change from 3 to 4. Some aspects of this decision remain controversial. Based on the characteristics of Hantaan virus (HTNV) and its role in the pathogenesis of hemorrhagic fever with renal syndrome, it might be difficult to develop an effective and safe HTNV vaccine through the isolate-inactivate-inject paradigm. With the development of high-throughput ‘omics’ technologies in the 21st century, vaccinomics has been introduced. While the goal of vaccinomics is to develop equations to describe and predict the immune response, it could also serve as a tool for developing new vaccine candidates and individualized approaches to vaccinology. Thus, the possibility of applying the innovative field of vaccinomics to develop a more effective and safer HTNV vaccine should be considered.
참고문헌 (29)
- "Online library of drugs and foods"[URL]
- Oh MD, "Milestones in history of adult vaccination in Korea", Clin Exp Vaccine Res, 1(1), pp.9~17 (2012)
- Halloran ME, "Design and interpretation of vaccine field studies", Epidemiol Rev, 21(1), pp.73~88 (1999)
- Chu YK, "A field efficacy trial of inactivated hantaan virus vaccine(Hantavax(TM))against hemorrhagic fever with renal syndrome(HFRS)in the endemic areas of Yugoslavia from 1996 to 1998", J Korean Soc Virol, 29(2), pp.55~64 (1999)
- Park K, "Protective effectiveness of hantavirus vaccine", Emerg Infect Dis, 10(12), pp.2218~2220 (2004)
- Jung J, "Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome", J Infect Dis, 217(9), pp.1417~1420 (2018)
- Sohn YM, "Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine(Hantavax) : consideration of active immunization in South Korea", Yonsei Med J, 42(3), pp.278~284 (2001)
- Krüger DH, "Human pathogenic hantaviruses and prevention of infection", Hum Vaccin, 7(6), pp.685~693 (2011)
- Avšič-Županc T, "Hantavirus infections", Clin Microbiol Infect, 21S, pp.e6~e16 (2019)
- Maes P, "Hantaviruses : immunology, treatment, and prevention", Viral Immunol, 17(4), pp.481~497 (2004)
- 이용진, "Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome", Kidney Research and Clinical Practice, 37(4), pp.366~372 (2018), 대한신장학회
- Oberg AL, "Systems biology approaches to new vaccine development", Curr Opin Immunol, 23(3), pp.436~443 (2011)
- Schmaljohn CS, "Vaccines for hantaviruses : progress and issues", Expert Rev Vaccines, 11(5), pp.511~513 (2012)
- Poland GA, "Vaccinology in the third millennium : scientific and social challenges", Curr Opin Virol, 17, pp.116~125 (2016)
- 오수진, "Systems Biology-Based Platforms to Accelerate Research of Emerging Infectious Diseases", Yonsei Medical Journal, 59(2), pp.176~186 (2018), 연세대학교의과대학[DOI]
- Poland GA, "Vaccinomics, adversomics, and the immune response network theory : individualized vaccinology in the 21st century", Semin Immunol, 25(2), pp.89~103 (2013)
- Poland GA, "Heterogeneity in vaccine immune response : the role of immunogenetics and the emerging field of vaccinomics", Clin Pharmacol Ther, 82(6), pp.653~664 (2007)
- Pulendran B, "Systems vaccinology", Immunity, 33(4), pp.516~529 (2010)
- De Gregorio E, "Vaccines for the future : learning from human immunology", Microb Biotechnol, 5(2), pp.149~155 (2012)
- Mooney M, "Systems immunogenetics of vaccines", Semin Immunol, 25(2), pp.124~129 (2013)
- Nakaya HI, "Vaccinology in the era of high-throughput biology", Philos Trans R Soc Lond B Biol Sci, 370(1671), pp.20140146~ (2015)
- Querec TD, "Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans", Nat Immunol, 10(1), pp.116~125 (2009)
- Gaucher D, "Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses", J Exp Med, 205(13), pp.3119~3131 (2008)
- Ackerman ME, "Systems serology for evaluation of HIV vaccine trials", Immunol Rev, 275(1), pp.262~270 (2017)
- Mooney M, "A systems framework for vaccine design", Curr Opin Immunol, 25(5), pp.551~555 (2013)
- Circelli L, "Systems biology approach for cancer vaccine development and evaluation", Vaccines(Basel), 3(3), pp.544~555 (2015)
- Petrizzo A, "Systems vaccinology for cancer vaccine development", Expert Rev Vaccines, 13(6), pp.711~719 (2014)
- Hagan T, "Systems vaccinology : enabling rational vaccine design with systems biological approaches", Vaccine, 33(40), pp.5294~5301 (2015)
- Poland GA, "Personalized vaccines : the emerging field of vaccinomics", Expert Opin Biol Ther, 8(11), pp.1659~1667 (2008)